NYSE:GSK - GlaxoSmithKline Stock Price, Price Target & More

GlaxoSmithKline trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK."

GlaxoSmithKline declared a quarterly dividend on Thursday, April 26th. Stockholders of record on Friday, May 11th will be paid a dividend of $0.5298 per share on Thursday, July 12th. This represents a $2.12 annualized dividend and a dividend yield of 5.18%. The ex-dividend date is Thursday, May 10th. View GlaxoSmithKline's Dividend History.

GlaxoSmithKline plc (NYSE:GSK) issued its earnings results on Wednesday, April, 25th. The pharmaceutical company reported $0.68 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.70 by $0.02. The pharmaceutical company earned $10.04 billion during the quarter, compared to analysts' expectations of $10.26 billion. GlaxoSmithKline had a net margin of 3.50% and a return on equity of 144.84%. View GlaxoSmithKline's Earnings History.

GlaxoSmithKline is scheduled to release their next quarterly earnings announcement on Wednesday, July, 25th 2018. View Earnings Estimates for GlaxoSmithKline.

13 brokerages have issued 12 month price targets for GlaxoSmithKline's shares. Their forecasts range from $35.85 to $40.00. On average, they anticipate GlaxoSmithKline's share price to reach $38.6167 in the next twelve months. View Analyst Ratings for GlaxoSmithKline.

GlaxoSmithKline saw a decline in short interest in May. As of May 31st, there was short interest totalling 8,497,397 shares, a decline of 27.2% from the May 15th total of 11,675,520 shares. Based on an average trading volume of 2,406,543 shares, the short-interest ratio is presently 3.5 days. View GlaxoSmithKline's Current Options Chain.

Some companies that are related to GlaxoSmithKline include Johnson & Johnson (JNJ), Pfizer (PFE), Novartis (NVS), Merck & Co., Inc. (MRK), AbbVie (ABBV), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), Sanofi (SNY), Bayer (BAYRY), Eli Lilly And Co (LLY), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Allergan (AGN), Celgene (CELG) and Shire (SHPG).

Press coverage about GSK stock has been trending somewhat positive this week, according to Accern Sentiment. Accern identifies positive and negative press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. GlaxoSmithKline earned a news impact score of 0.10 on Accern's scale. They also gave media coverage about the pharmaceutical company an impact score of 45.90 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future.

GlaxoSmithKline's stock is owned by a number of of institutional and retail investors. Top institutional investors include Royal Bank of Canada (0.86%), Fisher Asset Management LLC (0.54%), Federated Investors Inc. PA (0.17%), Northern Trust Corp (0.13%), Equity Investment Corp (0.13%) and Schafer Cullen Capital Management Inc. (0.08%). View Institutional Ownership Trends for GlaxoSmithKline.

GSK stock was sold by a variety of institutional investors in the last quarter, including Royal Bank of Canada, Millennium Management LLC, Federated Investors Inc. PA, SeaTown Holdings Pte. Ltd., PVG Asset Management Corp, Envestnet Asset Management Inc., SG Americas Securities LLC and Thrivent Financial for Lutherans. View Insider Buying and Selling for GlaxoSmithKline.

GSK stock was acquired by a variety of institutional investors in the last quarter, including Equity Investment Corp, Schafer Cullen Capital Management Inc., Fisher Asset Management LLC, BlackRock Inc., LPL Financial LLC, CIBC World Markets Inc., Northern Trust Corp and Summit Trail Advisors LLC. View Insider Buying and Selling for GlaxoSmithKline.

Shares of GSK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of GSK stock can currently be purchased for approximately $40.89.

GlaxoSmithKline has a market capitalization of $101.19 billion and generates $38.89 billion in revenue each year. The pharmaceutical company earns $1.97 billion in net income (profit) each year or $2.88 on an earnings per share basis. GlaxoSmithKline employs 99,827 workers across the globe.

GlaxoSmithKline's mailing address is 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0, TW8 9GS. The pharmaceutical company can be reached via phone at 44-20-8047-5000 or via email at [email protected]